Moderna (MRNA) Secures Nasdaq-100 Spot Despite Citi’s Sell Rating

Key Takeaways

• Moderna shares gained 2.2% in pre-market hours, reaching $193.15, following official confirmation of its addition to the Nasdaq-100 Index on October 9.
• The biotech firm takes the spot previously held by Warner Bros. Discovery, which exits the index due to its $81 billion acquisition by Paramount Skydance closing October 6.
• Year-to-date performance shows MRNA shares soaring approximately 553%, bringing the company’s market capitalization to around $75.4 billion.
• Citi’s Geoff Meacham issued a Sell rating on MRNA, arguing that the stock’s meteoric rise exceeds what its cancer treatment pipeline can realistically justify.
• Consensus among Wall Street analysts remains at Hold, with the average target price suggesting potential downside of 42% from current levels.

Moderna shares advanced 2.2% during Friday’s pre-market session, hitting $193.15 after Nasdaq officially confirmed the biotech company’s inclusion in the Nasdaq-100 Index effective before the opening bell on October 9.

Moderna, Inc., MRNA

This development has nothing to do with clinical breakthroughs. Instead, it’s purely an index rebalancing event.

The Cambridge-based vaccine maker will take over the position currently occupied by Warner Bros. Discovery, which is exiting the index following its acquisition by Paramount Skydance in an $81 billion transaction. A federal judge recently gave the green light to a settlement that removes the final hurdle for the merger, scheduled to finalize on October 6.

When Moderna officially enters the index, passive funds benchmarked to the Nasdaq-100 must purchase shares. With more than $800 billion in assets tracking this index, even minor adjustments can generate significant demand.

Remarkable 2025 Performance for MRNA

The year has been nothing short of exceptional for Moderna shareholders. The stock has skyrocketed roughly 553% year-to-date, propelling the company’s valuation to approximately $75.4 billion.

The lion’s share of this explosive growth stems from encouraging Phase 3 data for intismeran autogene, Moderna’s personalized melanoma vaccine developed in partnership with Merck. Since those interim findings were unveiled, shares have climbed about 222%.

Currently, Moderna trades near its 52-week peak of $208.90. This represents a stunning reversal for a company whose shares languished for years following the decline of pandemic-driven vaccine revenues.

Broader market strength provided a tailwind as well. On the session, the S&P 500 climbed 0.5%, the Dow Jones Industrial Average advanced 0.5%, and the Nasdaq Composite rose 0.8%. Meanwhile, industry peers BioNTech and Pfizer traded essentially flat, indicating this rally is company-specific rather than sector-driven.

Skepticism Emerges on Wall Street

The enthusiasm isn’t universal among market watchers. Days before the Nasdaq-100 announcement, Citi analyst Geoff Meacham slapped a Sell rating on Moderna, downgrading from Neutral.

While he bumped his price target up to $80 from $60, the rating change delivers an unmistakable message: Meacham believes the stock has climbed beyond what fundamentals support.

His thesis hinges on financial projections. According to Citi’s calculations, Moderna would require approximately $13 billion in annual oncology revenue to warrant a $200 share price. That figure represents nearly seven times Citi’s current forecast for the company’s cancer treatment segment.

Meacham characterized such sales expectations as implausible.

Yet buyers returned the following trading day despite the downgrade. That rebound has extended into this week’s pre-market action, with shares posting additional gains.

The Street’s overall stance remains cautious. Among the 20 analysts who have issued ratings in the last three months, the consensus lands at Hold for MRNA.

Their average price target stands at $110.44—roughly 42% beneath current trading levels. This substantial disconnect illustrates just how polarized views have become on the stock’s valuation.

In related corporate news, Moderna recently established a Chief Operating Officer position and named Juan Andres to fill it. The appointment aims to bolster the company’s manufacturing capabilities as its oncology programs advance toward commercialization.

Market participants are now focused on October 24, when Moderna plans to unveil additional data at the ESMO conference. That event could serve as the next major driver for share price movement in either direction.